Medical World News: Precision Medicine in Oncology

Published: Tuesday, Feb 02, 2016
According to the summary statement in the report, the PMI Cohort Program (PMI-CP) is planning to build a cohort of at least one million Americans. The working group has provided detailed guidance on 6 main topics in its report: cohort assembly, participant engagement, data, biobanking, policy, and governance. The report also provides direction for an optimal design of the PMI cohort, including:
  • The development of quantitative estimates of risk for a range of diseases by integrating environmental exposures, genetic factors, and gene-environment interactions
  • Identifying determinants of individual variation in efficacy and safety of commonly-used therapeutics
  • Developing biomarkers to assess risk of common diseases
  • Use of mobile health technologies to correlate activity, physiologic measures, and environmental exposures with health outcomes
  • Determine health impact of heterozygous or loss-of-function mutations
  • Developing new disease classification or relationships
  • Empower participants with enough information/data to better manage their health
  • Create platforms to enable trials of targeted therapy.
During the call, Collins discussed plans to start recruitment of study volunteers next year. Initial genetic testing will only include genotyping (which would cost $30 to $40 per person) rather than whole genomic sequencing, which is the ultimate goal.

President Obama’s request for $130 million for the study portion of the project is still under consideration with the lawmakers. Enrollees would include new volunteers who wish to participate and those who have already enrolled in large study cohorts through their health plans, such as Geisinger Health System, Kaiser Permanente, Mayo Clinic, and Marshfield Clinic.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication